Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Immunovant Inc (Symbol: IMVT) entered into oversold territory, hitting an RSI reading of 29 ...

(Reuters) -Boeing on Tuesday denied fluctuations in the production of its 737 MAX jetliner after an industry publication said it had hit a key target only to fall back due to industrial delays.

Main products in the clinical stage include: Batoclimab (HBM9161) is the first anti-FcRn monoclonal antibody completed Phase I to pivotal trials in China. As a novel, fully human anti-FcRn ...